Ruti Aga: Two Years for the Drug, Four for the Paper

Three verification checks appear in the Athletics Integrity Unit's (AIU) statement of Thursday, and all three failed in different ways. First — the clinic named on the prescription did not exist. Second — the person who wrote it was a family member with no medical registration. Third — that person claimed to have used "an old prescription pad from a former workplace," and the clinic flatly disowned it. Three independent verifications, three straight rejections.

Ruti Aga. Age 32. Ethiopia. Winner of the 2026 Tokyo Marathon. A six-year ban, counted from 10 September — the same date as her provisional suspension, with no year stated in the statement. Here is the number that reorganises the whole story: of the six years, two belong to the drug. The other four belong to the piece of paper she had manufactured.

What happened, and what was left out

A half marathon in China in March, which she won. An in-competition sample taken after the win, which returned methylprednisolone. The statement gives no race name, no time, no splits, no field depth. That must be stated plainly, because no performance judgment is possible here — anyone who writes "she was returning to form" is selling an inference. One fact survives: she won that race, which means a label-tier elite field with in-competition testing was present.

The pharmacology is the decisive hinge, and most reporting has fumbled it. Methylprednisolone is not an anabolic steroid; it is a glucocorticoid — WADA Prohibited List class S9 — and it is prohibited in-competition only, by injection, oral or rectal route. A therapeutic knee injection out of competition is entirely legal. A road race's testing window opens at 23:59 the day before the race. The case turned not on "did she take a steroid" but on route and timing.

Her record: the 2026 Tokyo title and three second-place finishes at World Marathon Majors. Second at Berlin 2026, first at Tokyo 2026 — those figures come from my own records; the source states no personal best, so treat them as pending verification.

The arithmetic: two plus four

The AIU imposed two years for the presence violation and four for tampering. The arithmetic matches standard Code sanctions and carries a message. Two years is the band applied to a Specified Substance where intent is unproven — precisely where a no-significant-fault argument normally shaves the period down. The panel did not grant that mitigation. Four years is the standard tampering sanction, and it came not from a document but from statements made in an interview during the investigation.

Backdating to 10 September is not relief. Provisional suspension time counts against the ban; that is procedural convenience, not a discount. Six years at 32 means a return at roughly 38. Within Ethiopia's women's marathon depth, even a 2:18 performer is not automatically selectable; a 38-year-old returning with a doping record is effectively unselectable. On paper the ban is six years; in practice it is a career.

The defence that existed, and was destroyed by hand

This is where the case departs from ordinary doping files. Because S9 is prohibited only in-competition, Aga had a legitimate pathway: documented knee pathology, the injection date, the route, a compliant washout interval before the race — or an application for a therapeutic use exemption. With real records, this might have ended in a reprimand rather than a sanction, and no tampering charge would have existed at all.

The forged prescription destroyed exactly that defence. Three verification failures are aggravating, not mitigating circumstances. One thing the coverage missed: manufacturing a prescription is itself circumstantial evidence of concealment intent, yet it did not escalate the presence sanction — the two and the four were kept in separate accounts.

The injury is the root; the paper is the symptom

In my experience, chronic knee pathology is the most common load-bearing failure in high-mileage marathoners, and a knee glucocorticoid injection is its cheapest, most available remedy. The road-racing economy oils this: appearance fees read form, not injury. Pressure builds to mask pain, and that pressure escapes where there is no team physician.

No team physician appears anywhere in Aga's file. What the statement shows is the absence of professional medical support — no registered physician, no TUE infrastructure, no habit of keeping records. This is bigger than an individual lapse; it is the signature of a governance gap institutionalised inside East African road-running entourages. The AIU named only the family member; whether an agent or management was investigated is not stated.

China's label-race circuit has become the income tier between Majors for East African runners — few races, high fees, low risk. That same tier is now the AIU's highest-yield testing ground. Two economies are colliding inside the same race. The lesson for India is direct: very few people in our camps know the difference between "a prohibited substance" and "a substance prohibited in competition" — and that difference is what stands between a warning and four years.

What was reported wrongly

Several reports called methylprednisolone a "prohibited steroid." Technically that is wrong — the S9 glucocorticoid condition is presence in-competition. Two costs follow. First, the reader files this alongside anabolic-steroid cases, where both intent and benefit are usually legible; here neither was proven. Second, and larger, the error makes invisible the defence that actually existed. "She cheated" and "she treated a knee and then panicked into paperwork" produce very different readings of the case.

The second discomfort: a six-year ban for a substance with no proven endurance benefit will be quoted from both directions — as proof of AIU rigour, and as proof of disproportionate enforcement against African road runners. The regional distribution of sanctions is not public, so that argument will run on inference for now.

Third, and this is my beat. Aga won one Major and finished second in three — a 2:18 to 2:20 athlete. Coverage of that record was close to nil; this case produced her first real headline. When I wrote the first issue of my newsletter on the 2026 Asian Athletics Championships in Bhubaneswar, I measured the same asymmetry: women won 12 of India's 29 medals and received 18 percent of media mentions. Women's road racing gets covered when it becomes a scandal, not when it runs 2:18.

Forward

The AIU statement omits one thing, and it is the most important: the scope of disqualification. Whether the March result and its prize money are annulled, and from which date ranking points are void — that fits in a single line and was not written. An organisation that wants to be a transparency benchmark should not leave the same kind of hole in its own paperwork.

The larger question: the next time a runner takes a knee injection and lines up, who tells her where the route-and-timing limits sit? That knowledge lives with a team doctor, not in a federation circular — and the athletes without a team doctor are the ones who become the next case.